Computer-based assessment of cognitive functions in brain tumor patients.
NeuroCogFX is a short yet comprehensive computer-based neuropsychological battery of tests developed to investigate neurological patients for cognitive dysfunction after potentially neurotoxic therapy. NeuroCogFX had been standardized in a group of 242 healthy controls (Fliessbach et al., Fortschr Neurol Psychiatr 74:643-650, 2006). The present study was conducted to assess the practicability, reliability, and validity of NeuroCogFX in brain tumor patients without active disease after tumor-directed therapy. To evaluate its validity, neuropsychological testing with NeuroCogFX was completed parallel to a battery of established neuropsychological tests in 54 patients with different types of brain tumors and without active disease for at least 6 months. Retest reliability was assessed in a different sample of 49 patients with gliomas. Results showed good practicability with a median test duration of 28 min (range 16-51 min). Most subtests showed medium-sized retest reliability in healthy controls and tumor patients, with the exception of the 2-back test and reaction time measures in tumor patients. Convergent validity was confirmed for the domains psychomotor speed, verbal memory, and verbal short-term memory. NeuroCogFX enables serial scientific neuropsychological assessment of brain tumor patients. It can be carried out within a short period of time by non-academic personnel and is therefore applicable to large cohorts, e.g., within clinical trials.
Fliessbach
Klaus
K
Department of Epileptology, University of Bonn, Bonn, Germany.
Rogowski
Sabine
S
Hoppe
Christian
C
Sabel
Michael
M
Goeppert
Mathias
M
Helmstaedter
Christoph
C
Calabrese
Pasquale
P
Schackert
Gabriele
G
Tonn
Joerg-Christian
JC
Simon
Matthias
M
Schlegel
Uwe
U
D000293:Adolescent; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000145:classification / Q000150:complications*; D003072:Cognition Disorders / Q000175:diagnosis* / Q000209:etiology*; D003936:Diagnosis, Computer-Assisted / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination; D009483:Neuropsychological Tests; D025341:Principal Component Analysis; D012016:Reference Values; D015203:Reproducibility of Results; D055815:Young Adult
Semin Oncol. 2003 Dec;30(6 Suppl 19):45-8
14765385
Fortschr Neurol Psychiatr. 2006 Nov;74(11):643-50
17103364
Radiother Oncol. 1996 Oct;41(1):55-9
8961368
Neurology. 2002 Jul 9;59(1):121-3
12105319
J Clin Oncol. 1994 Mar;12(3):627-42
8120563
Neuropsychol Rev. 1995 Sep;5(3):203-21
8653109
Cancer. 1994 Nov 15;74(10):2828-35
7954244
Neurology. 2005 Apr 12;64(7):1184-8
15824344
J Clin Oncol. 1998 Jun;16(6):2195-201
9626221
Neurology. 2004 Feb 24;62(4):548-55
14981169
Epilepsy Behav. 2009 Oct;16(2):298-310
19733124
J Neurooncol. 2007 Jan;81(2):175-84
16850104
J Neurooncol. 1999 Jul;43(3):277-86
10563434
J Clin Oncol. 2003 Jul 1;21(13):2519-24
12829670
Lancet. 2002 Nov 2;360(9343):1361-8
12423981
Neurology. 2001 May 22;56(10):1285-90
11376174
J Clin Oncol. 1998 Mar;16(3):859-63
9508166
Lancet Neurol. 2004 Mar;3(3):159-68
14980531
Recent Results Cancer Res. 2009;171:165-74
19322544
Ann Oncol. 2007 Jul;18(7):1145-51
17284616